Forbes Asia recently published 2015 annual honor roll of Asia Pacific’s 50 best listed companies (Asia’s Fab 50). Representing CGE’s fermentation technology platform, Huadong Medicine Co., Ltd. (“Huadong Medicine”), became one of the nine pharmaceutical companies that made to the list. 

Forbes Asia’s Fab 50 has been published for ten years. It is noteworthy that, compared with nine this year, back in 2005 there was only one company in healthcare sector made to the list, which shows how booming the healthcare industry has been.

Huadong Medicine mainly engages in the manufacture and sales of immunosuppressive drugs, TCM, synthetic pharmaceuticals and genetically engineered drugs, and in wholesale and distribution of Western medicine and TCM, medicinal herbs and medical devices. It is a listed major pharmaceutical company with integrated R&D, manufacture, distribution and logistics. It also undertakes state, provincial and city level government special drug reserve tasks. In recent years, Huadong Medicine has been growing steadily and has earned many awards, including “Top 20 most Competitive Public Pharmaceutical Companies in China”, “Fortune China 500 company” and “Top 10 Pharmaceutical Companies of the Year in Investment Value”.

Healthcare has become Huadong Medicine’s fourth core business sector after Western medicine, TCM and medical devices. Huadong Medicine is now recognized as a pioneer in the “Big Health” sector with its innovations and new projects.

2015 Forbes Asia’s Fab 50 – Healthcare